CLSM Aids in Non-invasive In Vivo Detection and Quantification of Demodex Mites

Confocal laser scanning microscopy (CLSM) enables the possibility to non-invasively detect, image, and quantify Demodex mites in facial skin of patients with rosacea. Researchers examined 25 patients (34-79 years of age) with facial rosacea and 25 age- and gender-matched normal controls by CLSM. They created mosaics of 8x8mm and 5x5mm by scanning horizontal layers of lesional skin, and quantification of the mites per follicle and per area as well as of the follicles per area was performed. In all patients, Demodex folliculorum could be detected by CLSM and presented as roundish or lengthy cone-shaped structures. Moreover, CLSM allowed the quantification of Demodex mites and showed significant differences. Mean number of mites was 165.4 per 8x8mm area and 94.2 per 5x5mm area in the patients, compared to 34.7 and 22.4, respectively, in the controls. The corresponding mean number of mites per follicle was 0.7 and 0.8, respectively, in the patients and 0.1 and 0.2, respectively, in the controls.

—Br J Dermatol. June 20, 2012

Once-Daily Modified Release Doxycycline Found Effective For Papulopustular Rosacea

Modified-release doxycycline taken once daily has been found to be both safe and effective in the treatment of paulopustular rosacea. Researchers evaluated 1,421 patients in a per-protocol population comprised 826 patients on monotherapy, with 28.5 percent male participants and 71.5 percent female participants receiving 40mg modified-release capsule once daily. This specific 40mg capsule delivers 30mg immediate-release and 10mg as delayed release using specially designed beads, and is subantimicrobial with both single and repeated dosing, according to the researchers. Results showed significant improvements in severity rating and erythema in males and females as demonstrated by shifts in the distribution of IGA and CEA scores between baseline and week 12. Treatment success at week 12 was achieved in 73.2 percent of males and in 75.2 percent of females. Adverse events were primarily mild or moderate gastrointestinal events and were reported in 9.9 percent of males and 12.8 percent of females.

—J Drugs Dermatol. 2012; 11(6): 703-707.

topical microemulsion system containing metronidazole for rosacea

A topical water-in-oil type microemulsion containing metronidazole was found to be effective in reducing symptoms of rosacea when compared with a commercial gel. After a six-week treatment period, researchers observed a statistically significant difference in reduction of the main symptoms of rosacea. Of the patients treated with the microemulsion, 17 percent experienced complete relief from inflammatory lesions, and 50 percent from erythema. The microemulsion resulted in complete relief in 38 percent of the patients with telangiectasia, while the commercial product did not provide any relief of telangiectasia symptoms.

—Chem Pharm Bull (Tokyo). 2012; 60(5): 583-92.